Biotech Investors & VC Firms in Montreal
16 firms in this list, with a median first check of $365K. Generated from verified public data and updated continuously.
BDC Venture Capital
MontrealPre-Seed–Growth$365K – $25.6M
109 people
Innovobot
MontrealPre-Seed–Series A$182.5K – $365K
31 people
Amplitude Venture Capital
MontrealPre-Seed–Series B
16 people
Finchley Healthcare Ventures
MontrealSeed–Series A
15 people
Sectoral Asset Management
MontrealSeries B–Late Stage
8 people
AmorChem
MontrealPre-Seed–Series A
5 people
BDC Life Sciences Venture Fund
MontrealSeed–Series A
2 people
Isenberg Ventures
MontrealSeed–Series A
2 people
AllosteRx Capital Management (Canada) Inc.
MontrealSeed–Series A
1 person
National Bank Technology Banking
MontrealGrowth
Persistence Capital Partners
MontrealGrowth–Late Stage
Boreal Ventures
MontréalPre-Seed–Seed$2.2M
27 people
AQC Capital
MontréalPre-Seed–Seed
20 people
CTI Life Sciences Fund L.P.
MontréalSeed–Late Stage
9 people
La Caisse
MontréalGrowth–Late Stage
1 person
adMare BioInnovations
VancouverSeed
Frequently asked questions
- Who are the top biotech investors & vc firms in montreal?
- Top biotech investors & vc firms in montreal include BDC Venture Capital, Innovobot, Amplitude Venture Capital, Finchley Healthcare Ventures, Sectoral Asset Management, AmorChem, BDC Life Sciences Venture Fund, Isenberg Ventures — 16 firms in total meet the criteria.
- What is the typical first check among biotech investors & vc firms in montreal?
- The median first check among the 16 biotech investors & vc firms in montreal tracked here is $365K.
Related lists
Investors & VC Firms in North America (12938)Investors & VC Firms in United States (11976)Investors & VC Firms in Europe (5859)Investors & VC Firms in Global (4787)AI & Machine Learning Investors & VC Firms (4629)Fintech Investors & VC Firms (4588)SaaS Investors & VC Firms (4239)Healthtech Investors & VC Firms (4227)Enterprise Software Investors & VC Firms (4136)Crypto & Web3 Investors & VC Firms (3986)
Data sourced from public filings and firms' own websites — see our methodology.












































